首页 | 本学科首页   官方微博 | 高级检索  
检索        


MiR-137 suppresses tumor growth and metastasis in clear cell renal cell carcinoma
Authors:Meizhi Wang  Hui Gao  Haijun Qu  Jing Li  Kaili Liu  Zhiwu Han
Institution:1. Department of Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China;2. Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China;3. Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, China
Abstract:

Background

The most frequent type of renal cell carcinoma is called clear-cell renal cell carcinoma (ccRCC) which is associated with a poor prognosis. It has been observed that miR-137 is aberrantly expressed in many different kinds of human malignancies including ccRCC. This research aims to examine the role of miR-137 in ccRCC.

Methods

Quantitative RT-PCR (qRT-PCR) was applied to measure miR-137 expression in ccRCC and adjacent noncancerous tissue. Gene expression was determined by western blot. Cell Counting Kit-8 (CCK-8) assay, flow cytometry and Transwell assay were used to determine the effects of miR-137 on cell growth, apoptosis and invasion, respectively. Moreover, xenograft and pulmonary metastasis animal models were established to investigate the role of miR-137 in vivo.

Results

Our findings show that there was significant downregulation of miR-137 in ccRCC tissue relative to corresponding non-cancerous tissue. Ectopic miR-137 expression in ccRCC cells led to suppression of cell growth and invasion, as well as apoptosis induction. In contrast, knockdown of miR-137 enhances proliferation and invasion, inhibits apoptosis. It also confirms that miR-137 plays a tumor supressor role in vivo. Mechanically, miR-137 directly targets the 3′-UTR of RLIP76 which is an established oncogene in ccRCC.

Conclusion

MiR-137 serves as a tumor suppressor, which can be considered a potential therapeutic target in ccRCC.
Keywords:miR-137  ccRCC  RLIP76
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号